$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx

$egrx Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-Q Financial Statement

#000082787118000010 Filed on November 01, 2018

Income Statement

Concept	2018 Q4	2018 Q3	2017 Q3
Revenue	$56.05M	$51.34M	$63.02M
YoY Change	19.81%	-18.54%	66.58%
Cost Of Revenue	$18.56M	$8.621M	$4.815M
YoY Change	35.38%	79.04%	-53.81%
Gross Profit	$37.50M	$38.35M	$58.21M
YoY Change	13.35%	-34.12%	112.37%
Gross Profit Margin	66.89%	74.69%	92.36%
Selling, General & Admin	$15.48M	$13.88M	$16.67M
YoY Change	16.22%	-16.74%	42.95%
% of Gross Profit	41.29%	36.19%	28.64%
Research & Development	$5.860M	$5.975M	$8.954M
YoY Change	-37.92%	-33.27%	179.2%
% of Gross Profit	15.63%	15.58%	15.38%
Depreciation & Amortization	$840.0K	$840.0K	$950.0K
YoY Change	-11.58%	-11.58%	163.89%
% of Gross Profit	2.24%	2.19%	1.63%
Operating Expenses	$21.33M	$32.94M	$38.07M
YoY Change	-5.74%	-13.49%	49.15%
Operating Profit	$15.73M	$18.40M	$24.95M
YoY Change	50.6%	-26.24%	102.71%
Interest Expense	-$500.0K	$743.0K	$527.0K
YoY Change	0.0%	40.99%	17466.67%
% of Operating Profit	-3.18%	4.04%	2.11%
Other Income/Expense, Net		-$734.0K	-$492.0K
YoY Change		49.19%	-2239.13%
Pretax Income	$15.23M	$17.67M	$24.46M
YoY Change	53.22%	-27.76%	98.35%
Income Tax	$2.640M	$3.628M	$9.027M
% Of Pretax Income	17.33%	20.53%	36.91%
Net Earnings	$12.59M	$14.04M	$15.43M
YoY Change	38.5%	-9.01%	29.11%
Net Earnings / Revenue	22.46%	27.35%	24.49%
Basic Earnings Per Share	$0.86	$0.94	$1.03
Diluted Earnings Per Share	$0.84	$0.91	$0.98
COMMON SHARES
Basic Shares Outstanding	14.91M shares	15.01M shares	15.05M shares
Diluted Shares Outstanding		15.48M shares	15.76M shares

Balance Sheet

Concept	2018 Q4	2018 Q3	2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$78.80M	$91.20M	$97.50M
YoY Change	-31.3%	-6.46%	64.42%
Cash & Equivalents	$78.79M	$91.23M	$97.55M
Short-Term Investments
Other Short-Term Assets	$134.0K	$1.671M	$850.0K
YoY Change	-76.11%	96.59%	99.53%
Inventory	$8.304M	$7.273M	$4.878M
Prepaid Expenses
Receivables	$66.49M	$78.46M	$71.60M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$163.8M	$197.8M	$182.2M
YoY Change	-13.17%	8.57%	53.01%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.397M	$2.553M	$4.365M
YoY Change	-64.85%	-41.51%	54.4%
Goodwill	$39.74M	$39.74M	$39.74M
YoY Change	0.0%	0.0%
Intangibles	$18.10M	$18.70M	$24.00M
YoY Change	-22.38%	-22.08%	-3.06%
Long-Term Investments
YoY Change
Other Assets	$694.0K	$706.0K	$124.0K
YoY Change	459.68%	469.35%	31.91%
Total Long-Term Assets	$74.76M	$71.02M	$84.74M
YoY Change	-8.12%	-16.19%	206.13%
TOTAL ASSETS
Total Short-Term Assets	$163.8M	$197.8M	$182.2M
Total Long-Term Assets	$74.76M	$71.02M	$84.74M
Total Assets	$238.6M	$268.8M	$266.9M
YoY Change	-11.65%	0.71%	81.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.917M	$7.544M	$8.902M
YoY Change	-17.23%	-15.25%	-32.07%
Accrued Expenses	$23.52M	$22.87M	$20.44M
YoY Change	52.81%	11.88%	-4.19%
Deferred Revenue	$5.869M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$6.250M	$5.000M	$5.000M
YoY Change	28.21%	0.0%
Total Short-Term Liabilities	$39.69M	$35.41M	$34.40M
YoY Change	-16.1%	2.95%	-2.97%
LONG-TERM LIABILITIES
Long-Term Debt	$38.16M	$39.31M	$43.94M
YoY Change	-11.07%	-10.52%
Other Long-Term Liabilities	$0.00	$0.00	$17.50M
YoY Change	-100.0%	-100.0%	201.72%
Total Long-Term Liabilities	$38.16M	$39.31M	$43.94M
YoY Change	-11.07%	-10.52%	657.52%
TOTAL LIABILITIES
Total Short-Term Liabilities	$39.69M	$35.41M	$34.40M
Total Long-Term Liabilities	$38.16M	$39.31M	$43.94M
Total Liabilities	$77.84M	$74.72M	$78.33M
YoY Change	-13.71%	-4.61%	90.12%
SHAREHOLDERS EQUITY
Retained Earnings	$58.19M	$45.60M	$17.20M
YoY Change	121.38%	165.11%	-120.73%
Common Stock	$17.00K	$16.00K	$16.00K
YoY Change	6.25%	0.0%	6.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$153.9M	$103.4M	$75.79M
YoY Change	90.48%	36.45%	321.14%
Treasury Stock Shares	2.590M shares	1.583M shares	1.150M shares
Shareholders Equity	$160.8M	$194.1M	$171.1M
YoY Change
Total Liabilities & Shareholders Equity	$238.6M	$268.8M	$266.9M
YoY Change	-11.65%	0.71%	81.9%

Cashflow Statement

Concept	2018 Q4	2018 Q3	2017 Q3
OPERATING ACTIVITIES
Net Income	$12.59M	$14.04M	$15.43M
YoY Change	38.5%	-9.01%	29.11%
Depreciation, Depletion And Amortization	$840.0K	$840.0K	$950.0K
YoY Change	-11.58%	-11.58%	163.89%
Cash From Operating Activities	$38.10M	$3.690M	$7.890M
YoY Change	46.99%	-53.23%	-40.09%
INVESTING ACTIVITIES
Capital Expenditures	-$80.00K	-$30.00K	-$1.580M
YoY Change	-97.07%	-98.1%	-88.86%
Acquisitions
YoY Change
Other Investing Activities	$0.00		$0.00
YoY Change
Cash From Investing Activities	-$80.00K	-$30.00K	-$1.580M
YoY Change	-97.07%	-98.1%	-88.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-50.46M	-12.68M	35.84M
YoY Change	729.93%	-135.38%	-335.17%
NET CHANGE
Cash From Operating Activities	38.10M	3.690M	7.890M
Cash From Investing Activities	-80.00K	-30.00K	-1.580M
Cash From Financing Activities	-50.46M	-12.68M	35.84M
Net Change In Cash	-12.44M	-9.020M	42.15M
YoY Change	-172.71%	-121.4%	-359.38%
FREE CASH FLOW
Cash From Operating Activities	$38.10M	$3.690M	$7.890M
Capital Expenditures	-$80.00K	-$30.00K	-$1.580M
Free Cash Flow	$38.18M	$3.720M	$9.470M
YoY Change	33.26%	-60.72%	-65.37%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	4877000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	3750000	USD
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2018-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0000827871
CY2018Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	14913159	shares
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	EAGLE PHARMACEUTICALS, INC.
	dei	Entity Small Business EntitySmallBusiness	false
CY2017Q4	egrx	Accrued Product Costs Current AccruedProductCostsCurrent	2657000	USD
CY2018Q3	egrx	Accrued Product Costs Current AccruedProductCostsCurrent	4843000	USD
CY2017Q4	egrx	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	936000	USD
CY2018Q3	egrx	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	3160000	USD
CY2017Q4	egrx	Advancestocommercialmanufactures Advancestocommercialmanufactures	2389000	USD
CY2018Q3	egrx	Advancestocommercialmanufactures Advancestocommercialmanufactures	5012000	USD
CY2017Q3	egrx	Clinical Development Cost Sharing Percentage ClinicalDevelopmentCostSharingPercentage	0.5
CY2017Q4	egrx	Finite Lived Intangible Assets Impairment FiniteLivedIntangibleAssetsImpairment	7235000	USD
CY2018Q3	egrx	Finite Lived Intangible Assets Impairment FiniteLivedIntangibleAssetsImpairment	9939000	USD
	egrx	Increase Decreasein Prepaid Expenseand Other Current Assets Total IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal	-3227000	USD
	egrx	Increase Decreasein Prepaid Expenseand Other Current Assets Total IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal	5709000	USD
	egrx	License Agreement Potential Milestone Payments LicenseAgreementPotentialMilestonePayments	10000000	USD
CY2017Q3	egrx	License Agreement Proceeds From Upfront Payment LicenseAgreementProceedsFromUpfrontPayment	12500000	USD
CY2017Q4	egrx	Number Of Clinical Trial Sites NumberOfClinicalTrialSites	12	site
CY2018Q3	egrx	Number Of Products NumberOfProducts	2	product
CY2018Q3	egrx	Obligations Future Payments ObligationsFuturePayments	80878000	USD
CY2018Q3	egrx	Obligations Future Payments Due In Fifth Year ObligationsFuturePaymentsDueInFifthYear	703000	USD
CY2018Q3	egrx	Obligations Future Payments Due In Fourth Year ObligationsFuturePaymentsDueInFourthYear	699000	USD
CY2018Q3	egrx	Obligations Future Payments Due In Second Year ObligationsFuturePaymentsDueInSecondYear	31035000	USD
CY2018Q3	egrx	Obligations Future Payments Due In Third Year ObligationsFuturePaymentsDueInThirdYear	39728000	USD
CY2018Q3	egrx	Obligations Future Payments Due Next Twelve Months ObligationsFuturePaymentsDueNextTwelveMonths	7710000	USD
CY2018Q3	egrx	Obligations Future Payments Due Thereafter ObligationsFuturePaymentsDueThereafter	1003000	USD
	egrx	Paymentsfor Contingent Consideration PaymentsforContingentConsideration	0	USD
	egrx	Paymentsfor Contingent Consideration PaymentsforContingentConsideration	15001000	USD
CY2017Q4	egrx	Prepaid Fda User Fee PrepaidFDAUserFee	1369000	USD
CY2018Q3	egrx	Prepaid Fda User Fee PrepaidFDAUserFee	1240000	USD
CY2017Q4	egrx	Prepaid Research And Development PrepaidResearchAndDevelopment	1069000	USD
CY2018Q3	egrx	Prepaid Research And Development PrepaidResearchAndDevelopment	0	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11981000	USD
CY2018Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	7544000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	53821000	USD
CY2018Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	78461000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15391000	USD
CY2018Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	22867000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1254000	USD
CY2018Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1740000	USD
CY2017Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	4310000	USD
CY2018Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	6335000	USD
CY2017Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	4811000	USD
CY2018Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	4119000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	233639000	USD
CY2018Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	251875000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14512000	USD
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3728000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11618000	USD
CY2018Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4472000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14512000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	128000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	282000	USD
CY2017Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	711000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2135000	USD
CY2018Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	599000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1916000	USD
CY2017Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1671570	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1580277	shares
CY2018Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1704348	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1810098	shares
CY2017Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	7235000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	7235000	USD
CY2018Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	2704000	USD
CY2017Q4	us-gaap	Assets Assets	270060000	USD
CY2018Q3	us-gaap	Assets Assets	268788000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	188697000	USD
CY2018Q3	us-gaap	Assets Current AssetsCurrent	197770000	USD
CY2017Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-6452000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-5604000	USD
CY2018Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-763000	USD
CY2017Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	15055000	USD
CY2018Q3	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	0	USD
CY2017Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	709000	USD
CY2018Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	0	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52820000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	97545000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	114657000	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	91226000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	44725000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-23431000	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16503283	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	16000	USD
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16089439	shares
CY2018Q3	us-gaap	Common Stock Value CommonStockValue	16000	USD
CY2017Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4815000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	24490000	USD
CY2018Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8621000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	29919000	USD
CY2018Q3	us-gaap	Deferred Finance Costs Noncurrent Gross DeferredFinanceCostsNoncurrentGross	700000	USD
CY2017Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	11354000	USD
CY2018Q3	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	9314000	USD
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	12141000	USD
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	2040000	USD
	us-gaap	Depreciation Depreciation	657000	USD
	us-gaap	Depreciation Depreciation	918000	USD
CY2017Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.03
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.82
CY2018Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.94
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.30
CY2017Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.98
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.68
CY2018Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.91
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.25
CY2017Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.37
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.32
CY2018Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.21
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.03
CY2017Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3763000	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	5679000	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	8925000	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	599000	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1369000	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2623000	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2666000	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2520000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	34320000	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	34320000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	23322000	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	18702000	USD
CY2017Q4	us-gaap	Goodwill Goodwill	39743000	USD
CY2018Q3	us-gaap	Goodwill Goodwill	39743000	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	24458000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	63006000	USD
CY2018Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	17668000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	18804000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	8845000	USD
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9027000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	20148000	USD
CY2018Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3628000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-509000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	1887000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-5814000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4437000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	29407000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	24640000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-4049000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	7476000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2139000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4525000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-12000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	582000	USD
CY2017Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	716443	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	840625	shares
CY2018Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	471878	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	578823	shares
CY2017Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	23322000	USD
CY2018Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	18702000	USD
CY2017Q3	us-gaap	Interest Expense InterestExpense	527000	USD
	us-gaap	Interest Expense InterestExpense	594000	USD
CY2018Q3	us-gaap	Interest Expense InterestExpense	743000	USD
	us-gaap	Interest Expense InterestExpense	2118000	USD
	us-gaap	Interest Paid InterestPaid	0	USD
	us-gaap	Interest Paid InterestPaid	1540000	USD
CY2017Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1698000	USD
CY2018Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	329000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	5118000	USD
CY2018Q3	us-gaap	Inventory Net InventoryNet	7273000	USD
CY2017Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2489000	USD
CY2018Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	6944000	USD
CY2017Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	931000	USD
CY2018Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	0	USD
CY2017Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	35000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	52000	USD
CY2018Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	9000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	36000	USD
CY2017Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	184000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	503000	USD
CY2018Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	135000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	423000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	270060000	USD
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	268788000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	47302000	USD
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	35411000	USD
CY2018Q3	us-gaap	Long Term Debt LongTermDebt	45000000	USD
CY2017Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	4875000	USD
CY2018Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	5000000	USD
CY2018Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	0	USD
CY2018Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	1250000	USD
CY2018Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	0	USD
CY2018Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	0	USD
CY2018Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	38750000	USD
CY2018Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	5000000	USD
CY2018Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	1250000	USD
CY2017Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	42905000	USD
CY2018Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	39312000	USD
CY2017Q3	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	2568000	USD
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	17296000	USD
CY2018Q3	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	609000	USD
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	2622000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14183000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-37655000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2456000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-52000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	32998000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	14276000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	15431000	USD
	us-gaap	Net Income Loss NetIncomeLoss	42858000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	14040000	USD
	us-gaap	Net Income Loss NetIncomeLoss	19313000	USD
CY2017Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	15431000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	42858000	USD
CY2018Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	14040000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	19313000	USD
CY2017Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-492000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-542000	USD
CY2018Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-734000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2082000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	38071000	USD
	us-gaap	Operating Expenses OperatingExpenses	126374000	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	32935000	USD
	us-gaap	Operating Expenses OperatingExpenses	136372000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	24950000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	63548000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	18402000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	20886000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	4904000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	265000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	703000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	699000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	978000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1256000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	1003000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1423000	USD
CY2018Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1070000	USD
CY2017Q4	us-gaap	Other Assets Current OtherAssetsCurrent	561000	USD
CY2018Q3	us-gaap	Other Assets Current OtherAssetsCurrent	1671000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	124000	USD
CY2018Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	706000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	38790000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	22628000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	1192000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	4877000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	750000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1706000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	52000	USD
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2018Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15101000	USD
CY2018Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	20810000	USD
CY2017Q4	us-gaap	Prepaid Insurance PrepaidInsurance	116000	USD
CY2018Q3	us-gaap	Prepaid Insurance PrepaidInsurance	389000	USD
CY2017Q4	us-gaap	Prepaid Taxes PrepaidTaxes	9597000	USD
CY2018Q3	us-gaap	Prepaid Taxes PrepaidTaxes	12498000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	50000000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4165000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	8601000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6820000	USD
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2553000	USD
CY2018Q3	us-gaap	Purchase Obligation PurchaseObligation	30974000	USD
CY2018Q3	us-gaap	Purchase Obligation Due After Fifth Year PurchaseObligationDueAfterFifthYear	0	USD
CY2018Q3	us-gaap	Purchase Obligation Due In Fifth Year PurchaseObligationDueInFifthYear	0	USD
CY2018Q3	us-gaap	Purchase Obligation Due In Fourth Year PurchaseObligationDueInFourthYear	0	USD
CY2018Q3	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	6195000	USD
CY2018Q3	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	24779000	USD
CY2018Q3	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	0	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8954000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23163000	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5975000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	38560000	USD
CY2017Q3	us-gaap	Restructuring Charges RestructuringCharges	0	USD
	us-gaap	Restructuring Charges RestructuringCharges	0	USD
CY2018Q3	us-gaap	Restructuring Charges RestructuringCharges	91000	USD
	us-gaap	Restructuring Charges RestructuringCharges	7479000	USD
	us-gaap	Restructuring Costs RestructuringCosts	0	USD
	us-gaap	Restructuring Costs RestructuringCosts	5771000	USD
CY2017Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	0	USD
CY2018Q3	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	1600000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	26284000	USD
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	45597000	USD
CY2017Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	63021000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	189922000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	51337000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	157258000	USD
CY2017Q3	us-gaap	Royalty Expense RoyaltyExpense	6850000	USD
	us-gaap	Royalty Expense RoyaltyExpense	18990000	USD
CY2018Q3	us-gaap	Royalty Expense RoyaltyExpense	4370000	USD
	us-gaap	Royalty Expense RoyaltyExpense	13440000	USD
CY2017Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	16669000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	58100000	USD
CY2018Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13878000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	45033000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	11618000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	14512000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.3435
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.3697
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.4376
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.4376
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0218
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0242
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0290
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0294
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0179
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0179
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0272
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0230
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	925329	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	652625	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2324918	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2962629	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2786568	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2547992	shares
CY2018Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y29D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	107102	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	391609	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	180516	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	499592	shares
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	8601000	USD
CY2016Q3	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	75000000.0	USD
CY2017Q3	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	100000000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	179144000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	194065000	USD
CY2017Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	1241695	shares
CY2018Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	1582666	shares
	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	1582666	shares
	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	340971	shares
CY2017Q4	us-gaap	Treasury Stock Value TreasuryStockValue	80795000	USD
CY2018Q3	us-gaap	Treasury Stock Value TreasuryStockValue	103423000	USD
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	103400000	USD
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	22600000	USD
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	22628000	USD
CY2018Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2017Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	15764360	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	16015051	shares
CY2018Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	15483037	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	15482768	shares
CY2017Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15764360	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16015051	shares
CY2018Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15483037	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15482768	shares
CY2017Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15047917	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15174426	shares
CY2018Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15011159	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14903945	shares
	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Interim Condensed Consolidated Financial Statements</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim information and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for reporting on Form 10-Q. Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. The condensed consolidated balance sheet at December 31, 2017 was derived from audited financial statements, but certain information and footnote disclosures normally included in the Company's annual consolidated financial statements have been condensed or omitted. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary for the fair presentation of the financial information for the interim periods reported have been made. Results of operations for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results for the year ending December 31, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> or any period thereafter. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed with the SEC on February 26, 2018. Unless otherwise indicated or required by context, reference throughout to the "Company," "Eagle Pharmaceuticals," "Eagle," "we," "us" or "our" mean Eagle Pharmaceuticals, Inc., a Delaware corporation and its subsidiary, Eagle Biologics, Inc., and references to "Eagle Biologics" mean Eagle Biologics, Inc.</font></div></div>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassifications</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain reclassifications have been made to prior year amounts to conform with the current year presentation.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These financial statements are presented in U.S. dollars and are prepared in accordance with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements including disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period and accompanying notes. The Company's critical accounting policies are those that are both most important to the Company's financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0000827871-18-000010-index-headers.html	Edgar Link	pending
0000827871-18-000010-index.html	Edgar Link	pending
0000827871-18-000010.txt	Edgar Link	pending
0000827871-18-000010-xbrl.zip	Edgar Link	pending
egrx-20180930.xml	Edgar Link	completed
egrx-20180930.xsd	Edgar Link	pending
egrx-20180930_cal.xml	Edgar Link	unprocessable
egrx-20180930_def.xml	Edgar Link	unprocessable
egrx-20180930_lab.xml	Edgar Link	unprocessable
egrx-20180930_pre.xml	Edgar Link	unprocessable
egrx_q3x2018.htm	Edgar Link	pending
exhibit311q32018.htm	Edgar Link	pending
exhibit312q32018.htm	Edgar Link	pending
exhibit321q32018.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx

2018 Q4 Form 10-Q Financial Statement

#000082787118000010 Filed on November 01, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EGRX EAGLE PHARMACEUTICALS, INC. Stock $egrx

2018 Q4 Form 10-Q Financial Statement

#000082787118000010 Filed on November 01, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx